Although there was no statistically significant difference in overall mortality, an examination of the silymarin group's hepatitis C patient subgroup showed a clear trend toward fewer fatalities (Wenfeng et al., 2014 ).
← all excerpts
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.
1
—
—